- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Blood pressure control by sevoflurane administration during pediatric cardiopulmonary bypass
-
- Tani Seiji
- Department of Clinical Engineering, Mie University Hospital
-
- Takabayashi Shin
- 三重大学医学部付属病院 胸部心臓血管外科
-
- Ozu Yasuhisa
- 三重大学医学部付属病院 胸部心臓血管外科
-
- Nishikawa Yusaku
- Department of Clinical Engineering, Mie University Hospital
-
- Tomita Masayuki
- Department of Clinical Engineering, Mie University Hospital
-
- Kawano Toshiko
- Department of Clinical Engineering, Mie University Hospital
-
- Kureishi Yosuke
- Department of Clinical Engineering, Mie University Hospital
-
- Usami Shunsuke
- Department of Clinical Engineering, Mie University Hospital
-
- Yukimitsu Masahiro
- Department of Clinical Engineering, Mie University Hospital
-
- Iwata Hideki
- Department of Clinical Engineering, Mie University Hospital
-
- Shimpo Hideto
- 三重大学医学部付属病院 胸部心臓血管外科
Bibliographic Information
- Other Title
-
- 血管拡張薬としてのセボフルラン
- ―小児体外循環中の使用経験―
Search this article
Description
We have used sevoflurane(SEV)as a vasodilator during the pediatric cardio pulmonary bypass(CPB)from July 2010. The usefulness of the SEV as a vasodilator was investigated.<br>Eighteen infants under 7.5kg undergoing CPB were included. During aorta cross clamping, pump flow was maintained at 2.7L/min/m2 and mean systemic blood pleasure(SBP)was maintained at 35-55mmHg. If SBP exceeds 55mmHg, we used some vasodilators. By two vasodilator strategy, we compared group S(SEV: n=8)and group C(Control: n=10). In group S, SEV(0.5-2.0%)was administrated 25±16min after starting CPB as a main vasodilator. In C group, SBP was controlled at only 1-3mg bolus infusion of chlorpromazine.<br>Total amount of chlorpromazine was lower in group S(2±1mg)than in group C(9±4mg)(P<0.01). Although, in group C, there was no difference in SBP between at the start of CPZ and at the after 15min(56±11, 52±11mmHg), in group S, SBP was significantly decreased at the after 15min than at the start of SEV(58±6, 40±10mmHg)(P<0.01), and SBP was stabilized after that(after 20 min, 42±9mmHg). Furthermore, urine output during CPB was more in group S(206±113mL)than group C(86±93mL)(P=0.02).<br>By SEV administration as a vasodilator during pediatric CPB, not only rapid vasodilation but also maintenance of urine output were obtained, therefore SEV is an useful option as a vasodilator during pediatric CPB.
Journal
-
- Japanese Journal of Extra-Corporeal Technology
-
Japanese Journal of Extra-Corporeal Technology 39 (2), 132-137, 2012
The Japanese Society of Extra-Corporeal Technology in Medicine
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390001204655167616
-
- NII Article ID
- 10030810495
-
- NII Book ID
- AN1020635X
-
- ISSN
- 18845452
- 09122664
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed